$63.58 Million in Sales Expected for BioCryst Pharmaceutical

Equities research analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) to report sales of $63.58 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for BioCryst Pharmaceuticals’ earnings. The lowest sales estimate is $59.15 million and the highest is $65.34 million. BioCryst Pharmaceuticals reported sales of $49.96 million […]

Related Keywords

Canada , Switzerland , Swiss , Georgeb Abercrombie , Helenm Thackray , , Morgan Stanley , Biocryst Pharmaceuticals Company Profile Get Rating , Russell Investments Group Ltd , Zacks Investment Research , Swiss National Bank , Deutsche Bank , Nasdaq , Biocryst Pharmaceuticals , Cantor Fitzgerald , Biocryst Pharmaceuticals Inc , Royal Bank , Get Rating , Biocryst Pharmaceutical , Cryst Pharmaceuticals , Director George , Investments Group , National Bank , Cryst Pharmaceuticals Company Profile , Nasdaq Bcrx , Bcrx , Medical , 09058v10 , Ratings , Consensus ,